---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-252475"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2026-06-02T11:05:16+00:00"
generated_at: "2026-06-02T11:11:26.547953+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics announces FDA alignment on earlier eGFR analysis for atacicept; results expected Q3 2026

## Summary
- FDA agreed to revised ORIGIN 3 eGFR analysis plan to support potential full approval of atacicept in IgA Nephropathy.
- eGFR results now expected in the third quarter of 2026.
- Company plans to submit supplemental Biologics License Application for full approval in Q4 2026.
- Alignment could accelerate path to full approval for atacicept.

## SEC filing metadata
- accession: 0001193125-26-252475
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2026-06-02T11:05:16+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312526252475/0001193125-26-252475-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312526252475/vera-20260602.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-252475
- JSON: https://secwatch.observer/filing/0001193125-26-252475.json
- Plain text: https://secwatch.observer/filing/0001193125-26-252475.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.